IDH1 and central nervous system cancer: Focusing on non-GBM, by including 332 lower-grade gliomas (LGGs) from a Japanese cohort, compared with a total of 425 samples in TCGA, Suzuki et al.22 have identified a similar frequency of IDH1/2 mutation in the 2 cohorts, reaching 78.01% in the Japanese cohort and 80.47% in TCGA.